291 related articles for article (PubMed ID: 32418885)
21. Antiviral properties of placental growth factors: A novel therapeutic approach for COVID-19 treatment.
Joshi MG; Kshersagar J; Desai SR; Sharma S
Placenta; 2020 Sep; 99():117-130. PubMed ID: 32798764
[TBL] [Abstract][Full Text] [Related]
22. Pharmacological perspective: glycyrrhizin may be an efficacious therapeutic agent for COVID-19.
Luo P; Liu D; Li J
Int J Antimicrob Agents; 2020 Jun; 55(6):105995. PubMed ID: 32335281
[TBL] [Abstract][Full Text] [Related]
23. What would Sérgio Ferreira say to your physician in this war against COVID-19: How about kallikrein/kinin system?
Nicolau LAD; Magalhães PJC; Vale ML
Med Hypotheses; 2020 Oct; 143():109886. PubMed ID: 32504925
[TBL] [Abstract][Full Text] [Related]
24. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
25. Can beta-adrenergic blockers be used in the treatment of COVID-19?
Vasanthakumar N
Med Hypotheses; 2020 Sep; 142():109809. PubMed ID: 32388480
[No Abstract] [Full Text] [Related]
26. Is targeting Akt a viable option to treat advanced-stage COVID-19 patients?
Somanath PR
Am J Physiol Lung Cell Mol Physiol; 2020 Jul; 319(1):L45-L47. PubMed ID: 32519895
[No Abstract] [Full Text] [Related]
27. Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome.
van de Veerdonk FL; Netea MG; van Deuren M; van der Meer JW; de Mast Q; Brüggemann RJ; van der Hoeven H
Elife; 2020 Apr; 9():. PubMed ID: 32338605
[TBL] [Abstract][Full Text] [Related]
28. COVID-19 and chronological aging: senolytics and other anti-aging drugs for the treatment or prevention of corona virus infection?
Sargiacomo C; Sotgia F; Lisanti MP
Aging (Albany NY); 2020 Mar; 12(8):6511-6517. PubMed ID: 32229706
[TBL] [Abstract][Full Text] [Related]
29. Is SARS-CoV-2 associated with liver dysfunction in COVID-19 patients?
Ali N
Clin Res Hepatol Gastroenterol; 2020 Sep; 44(4):e84-e86. PubMed ID: 32471656
[No Abstract] [Full Text] [Related]
30. Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal.
Fantini J; Chahinian H; Yahi N
Int J Antimicrob Agents; 2020 Aug; 56(2):106020. PubMed ID: 32862840
[TBL] [Abstract][Full Text] [Related]
31. Cardiovascular Complications Associated with COVID-19 and Potential Therapeutic~Strategies.
Samidurai A; Das A
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32947927
[TBL] [Abstract][Full Text] [Related]
32. p38 MAPK inhibition: A promising therapeutic approach for COVID-19.
Grimes JM; Grimes KV
J Mol Cell Cardiol; 2020 Jul; 144():63-65. PubMed ID: 32422320
[TBL] [Abstract][Full Text] [Related]
33. Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy?
Batlle D; Wysocki J; Satchell K
Clin Sci (Lond); 2020 Mar; 134(5):543-545. PubMed ID: 32167153
[TBL] [Abstract][Full Text] [Related]
34. Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity.
Zhu Y; Yu D; Yan H; Chong H; He Y
J Virol; 2020 Jul; 94(14):. PubMed ID: 32376627
[TBL] [Abstract][Full Text] [Related]
35. Viral Coagulopathy in Patients With COVID-19: Treatment and Care.
Kipshidze N; Dangas G; White CJ; Kipshidze N; Siddiqui F; Lattimer CR; Carter CA; Fareed J
Clin Appl Thromb Hemost; 2020; 26():1076029620936776. PubMed ID: 32687449
[TBL] [Abstract][Full Text] [Related]
36. A brief review of interplay between vitamin D and angiotensin-converting enzyme 2: Implications for a potential treatment for COVID-19.
Malek Mahdavi A
Rev Med Virol; 2020 Sep; 30(5):e2119. PubMed ID: 32584474
[TBL] [Abstract][Full Text] [Related]
37. [Renin-Angiotensin-System (RAS) and COVID-19 - On The Prescription of RAS Blockers].
Kreutz R; Abd El-Hady Algharably E; Ganten D; Messerli F
Pneumologie; 2020 Sep; 74(9):611-614. PubMed ID: 32916743
[No Abstract] [Full Text] [Related]
38. Indomethacin and resveratrol as potential treatment adjuncts for SARS-CoV-2/COVID-19.
Marinella MA
Int J Clin Pract; 2020 Sep; 74(9):e13535. PubMed ID: 32412158
[TBL] [Abstract][Full Text] [Related]
39. Would ACEIs/ARBs be beneficial for COVID-19 patients without hypertension?
Huang Y; Xie C; Chen X; Hong Q; Huang H
Pharmacol Res; 2020 Sep; 159():104959. PubMed ID: 32505834
[No Abstract] [Full Text] [Related]
40. The association between obesity and poor outcome after COVID-19 indicates a potential therapeutic role for montelukast.
Almerie MQ; Kerrigan DD
Med Hypotheses; 2020 Oct; 143():109883. PubMed ID: 32492562
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
